Wednesday, 1 September 2010

Clinuvel adds to family (Wednesday, 1 September 2010) AS Clinuvel centralises operations at its new headquarters in Switzerland, the company has added a new skin-protectant molecule to its pipeline, CUV9900. Full Story... pSivida lifted on FDA news (Wednesday, 1 September 2010) DUAL-listed pSivida gained 5.2% overnight on the NASDAQ after its licensee Alimera was granted priority review status for eye drug Iluvien by the US Food and Drug Administration for a diabetic macular edema indication. Full Story...

Tuesday, 31 August 2010

Pharmaxis reps dance Quintiles-style (Tuesday, 31 August 2010) AS Pharmaxis chief executive Dr Alan Robertson returns to work on light duties, the company has finalised a sales and marketing agreement with powerhouse Quintiles for commercialisation of Bronchitol for cystic fibrosis in Europe. Full Story... In Silico: More signs the FDA is toughening up (Tuesday, 31 August 2010) IT’S no secret the US Food and Drug Administration has been under sustained pressure over the last few years to toughen up its approvals process. While the FDA has traditionally been regarded as one of the more conservative drug approvals agencies, a number of public scandals in recent years has increased public and legislative pressure on the agency to raise the barriers. Full Story... It's a Sunshine day (Tuesday, 31 August 2010) IN an important first Sunshine Heart physicians participating in clinical trials of the C-Pulse Heart Assist System for moderate heart failure have completed their first minimally invasive implants of the device at a leading US hospital. Full Story... Pam-beating rat whisperer makes debut (Tuesday, 31 August 2010) DRUG discoverer Bionomics has found its anti-anxiety and anti-depressant compound BNC210 reduced anxiety in rats without sedating them, as diazepam did. Full Story... Revenue Matters: Unilife, Sirtex, Halcygen and more (Tuesday, 31 August 2010) US-based Unilife Corporation has increased its net loss by 5840% to $US29.7 million as revenues declined by 43% and payroll costs increased. Full Story... Giaconda offloads trio, keeps duo (Tuesday, 31 August 2010) SYDNEY-based Giaconda has sold commercialisation company RedHill three patents and rights to future gastrointestinal treatments developed by Centre for Digestive Diseases or its medical director Professor Thomas Borody. Full Story... Capital Briefs: Neurodiscovery, Select, Australia Invest and more (Tuesday, 31 August 2010) NEURODISCOVERY has signed up Cunningham Peterson Sharbanee Securities as underwriters for a $718,577 capital raising to support its neuropathic pain compound-development program. Full Story... Bio People: CogState, IM Medical, Sigma and more (Tuesday, 31 August 2010) IM Medical chief executive Roman Najdecki will move on to greener pastures at the end of September after Mark Scott Radiology Group general manager and new IM director Sergio Del Vecchio took the reins as managing director yesterday. Full Story... Changes to members-only section of AusBiotech website (Tuesday, 31 August 2010) AUSBIOTECH is in the process of further developing the secure, members-only login area of the organisation’s website, and is considering a communications area for the exclusive use of member chief executives. Full Story...

Monday, 30 August 2010

Market Pulse: How 'bout a $20.5B takeover? (Monday, 30 August 2010) THE week holds some promise for biotech valuations, with strong leads from overseas markets and another major takeover move for a biotech major on the global stage. Full Story...

Saturday, 28 August 2010

Agenix gets leg-up (Saturday, 28 August 2010) AGENIX shareholders have taken on a new cornerstone investor after executive chairman Nicholas Weston called for a fresh start for the company “brought to its knees” by an acquisition and the theft of $5.5 million by jailed former chief executive Neil Ian Leggett. Full Story... Bio Briefs: Phosphagenics, IM Medical, RA (Saturday, 28 August 2010) TRANSDERMAL drug delivery developer Phosphagenics’s corporate adviser Southern Cross Equities has predicted a near-term payoff from an anti-cellulite cream based on a fat-basting drug that failed a Metabolic Pharmaceuticals testing. Full Story...

Friday, 27 August 2010

Clinuvel seeks thriller re-pigmentation (Friday, 27 August 2010) LATE-stage drug developer Clinuvel Pharmaceuticals will evaluate a sixth indication for its orphan drug Scenesse in patients with vitiligo, a skin pigmentation disorder which reportedly affected the late Michael Jackson. Full Story...

Thursday, 26 August 2010

Avexa's second date with destiny (Thursday, 26 August 2010) AS it called a meeting of shareholders to vote on what could be another “board spill”, Avexa’s board has labelled the extraordinary general meeting requested by largest investor Calzada as a “waste of time and cost”. Full Story... CogState-Quixote duo tackles concussed (Thursday, 26 August 2010) AS contract research organisation and neurological testing company CogState reports a 15% increase in annual profit to $1.6 million, it has officially launched the Axon Sports joint venture with a North American company that sold its last venture to Nike. Full Story... We were rebuffed: Avexa (Thursday, 26 August 2010) AVEXA’S board has told shareholders its investor Calzada rebuffed the board’s efforts to “engage in good faith” with the shareholder. Full Story... Capital Briefs: Phylogica, Select, Neurodiscovery and more (Thursday, 26 August 2010) PATERSONS Securities has fully underwritten drug-discovery company Phylogica’s $2.4 million capital raising after a recent Eli Lilly contract win. Full Story... Bio People: ANU, W+ES, IMBCom and more (Thursday, 26 August 2010) THREE early career researchers have accepted L’Oreal for Women in Science fellowships worth $60,000 as they investigate stem cells and breast cancer relapse, carbon capturing and malaria drug alterations for chloroquine-resistant parasites. Full Story... ImpediMed pulls another reimbursement win (Thursday, 26 August 2010) MEDICAL devices producer ImpediMed has signed its first managed care contract to provide L-Dex lymphoedema-detection technology for female breast cancer patients as a preferred provider to some 3.5 million members. Full Story... Unilife pinged (Thursday, 26 August 2010) AS Unilife Corporation takes on new debt to fund plant construction, the US-based company has responded to a “please explain” from ASX Compliance which queried a 16.5% drop in share price. Full Story... Bio Briefs: GTG, Starpharma, OMI and more (Thursday, 26 August 2010) GENETIC Technologies has settled two more disputes with US biotechnology companies. Full Story... Introducing the AusBiotech team (Thursday, 26 August 2010) A team of more than 100 people across the country are working with and for AusBiotech to grow and sustain the biotechnology industry in Australia, including its board, staff, state and special interest-based volunteer committees. Full Story...

Click here to read today's news stories.

Click here to read our complete archive.